You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A brief iPad based screening measure for HIV associated neurocognitive disorders
SBC: Digital Artefacts LLC Topic: 105Despite significance advances in anti retroviral treatments HIV associated neurocognitive disorder HAND remains prevalent and can affect a broad range of everyday activities An effective brief cognitive screen that could be implemented in busy HIV clinics where clinicians have limited time to provide care for patients with complex medical psychiatric and cognitive conditions has the poten ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An Automated Patient Chart Error Detection System for Radiation Therapy
SBC: Infondrian LLC Topic: 101Project Summary Abstract Every year approximately severe mistreatments happen in radiation therapy Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $ per claim settled or litigated The current method for detecting treatment errors is by a weekly patient chart check where each treatment record is manually reviewed on a weekly basis Thi ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A New Prostate Cancer Treatment to Improve Outcomes and Reduce Side-effects
SBC: PXALPHA, L.L.C. Topic: 102PROJECT SUMMARY ABSTRACT Among men prostate cancer is the most common non skin cancer and second leading cause of cancer death with over new diagnoses expected in Approximately of men will be diagnosed with prostate cancer in their lifetime Current treatment options for prostate cancer however have sub optimal incidences of side effects that have a significant impact on pa ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development
SBC: QRKANSWER LLC Topic: NCIDESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Antibody targeting of ADAM for treatment of triple negative breast cancer
SBC: ADECTO PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
CardioPort to Enable Intracardiac Beating Heart and Minimally Invasive Open Heart Surgery
SBC: Nido Surgical, Inc Topic: NHLBIDESCRIPTIONprovided by applicantThe goal of this Fast Track STTR project is to develop a novel CardioPortTM surgical device that will enable minimally invasive beating heart repair without use of cardiopulmonary bypassCPBThere is a critical unmet need for new instruments to improve the surgical repair of heart defects in childrenCurrent best surgical practices involve either open heart surgery wit ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing novel RPPA for the detection of metastatic prostate cancer
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 102PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health